Gadopiclenol (Elucirem™) for Contrast-Enhanced MRIBy KayeOctober 20, 20220 The US FDA granted regulatory approval to Gadopiclenol (Elucirem™), a new macrocyclic GBCA for use in adults and children aged 2 years and older, for contrast-enhanced MRI.
New Opioid Receptor Agonist Approved for Pruritus in Chronic Kidney Disease: Difelikefalin (Korsuva)By Rachel TanOctober 12, 20220 In end-stage chronic kidney disease (CKD), pruritus is a common and oftentimes exasperating symptom for patients in accompaniment to their…
Omlonti (Omidenepag Isopropyl) for the Reduction of Elevated Intraocular PressureBy KayeOctober 6, 20220 On 22 Sep 2022, the US FDA approved Omlonti® 0.002% eye drops for the reduction of elevated intraocular pressure. Read more
Risdiplam: Spinal Muscular Atrophy (SMA) TreatmentBy KayeSeptember 12, 20220 Risdiplam is the only disease-modifying therapy granted local market authorisation by HSA. Read about how it is used as a treatment for SMA
HSA approves Belimumab (Benlysta) for Lupus NephritisBy KayeSeptember 3, 20220 Belimumab is a fully human IgG1λ recombinant monoclonal antibody directed against B lymphocyte stimulator. Know more about its drug profile
Pralsetinib: Targeted Therapies for RET-Fusion Positive NSCLCBy KayeAugust 25, 20220 Pralsetinib is a RET receptor tyrosine kinase inhibitor used to treat metastatic RET-driven non-small cell lung cancer. Learn more
Thalidomide (Old Drug for New Indication: Multiple Myeloma)By KayeAugust 11, 20220 Thalidomide possesses immunomodulatory, anti-inflammatory and antiangiogenic effects. Find out why it is effective against Myeloma cells
Tepotinib (Tepmetko) for METex14-altered NSCLCBy KayeJuly 27, 20220 Tepotinib (Tepmetko) was recently approved for the use of Non-Small Cell Lung Cancer (NSCLC). Find out about the Phase II VISION trial here.
Immune Checkpoint Inhibitors in Oncology: Pembrolizumab (Keytruda)By KayeJuly 14, 20220 Tumours harness several strategies to avoid elimination by the immune system and exploiting the programmed cell death protein (PD1) is…
The Role of Dupilumab (Dupixent), an IL-4 Receptor Alpha Antagonist, in Atopic DermatitisBy KayeJune 30, 20220 Among the many new drug approved for the use of atopic dermatitis or eczema, dupilumab (Dupixent) is one of them. Find out about its evidence here.
